The new HDI Global US product addresses the unique risks of various life sciences entities, including biotechnology firms, specialty pharmaceutical manufacturers, distributors, and producers of both non-invasive and permanently implantable medical devices.
The offering also targets contract manufacturing organizations (CMO) and contract development manufacturing organizations (CDMO), as well as blood plasma manufacturers.
Marco Hensel (pictured), chief underwriting officer at HDI Global US, noted: “HDI is committed to providing our insureds with bespoke solutions within the life sciences segment.
“The launch of our US life sciences division is another example of HDI’s continued focus on growth within the region and to act as a true ‘partner in transformation’ for our clients in times of exceptional acceleration within the medical realm.”
Leading the company’s expansion into the US life sciences market is Brian Carlsen, who recently joined HDI as an assistant vice president. In his new role, Carlsen will focus on growing the company’s presence in the sector.
The new practice leader brings 16 years of underwriting experience, with a decade devoted exclusively to life sciences insurance. Prior to HDI, Carlsen was the underwriting manager and referral underwriter for the East region at a Fortune 500 insurer.
“HDI is excited to have Brian join our US casualty team,” commented Dani Maurer, head of HDI’s liability global risk division. “He brings extensive experience with small to large LS firms, underwriting accounts ranging from startups to large multinational corporations.
“His expertise will play a key role in HDI’s product line expansion within the US.”
What do you think about this story? Share your thoughts in the comments below.
